These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24427314)

  • 21. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LRRK2 R1441G in Spanish patients with Parkinson's disease.
    Mata IF; Taylor JP; Kachergus J; Hulihan M; Huerta C; Lahoz C; Blazquez M; Guisasola LM; Salvador C; Ribacoba R; Martinez C; Farrer M; Alvarez V
    Neurosci Lett; 2005 Jul; 382(3):309-11. PubMed ID: 15925109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.
    Häbig K; Walter M; Poths S; Riess O; Bonin M
    Neurogenetics; 2008 May; 9(2):83-94. PubMed ID: 18097693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
    Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
    Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.
    Gonzalez-Cano L; Menzl I; Tisserand J; Nicklas S; Schwamborn JC
    Mol Neurobiol; 2018 Apr; 55(4):3490-3498. PubMed ID: 28508149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease.
    Desplats P; Patel P; Kosberg K; Mante M; Patrick C; Rockenstein E; Fujita M; Hashimoto M; Masliah E
    Mol Neurodegener; 2012 Sep; 7():49. PubMed ID: 23017109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.
    Sloan M; Alegre-Abarrategui J; Wade-Martins R
    Biochem Soc Trans; 2012 Oct; 40(5):1080-5. PubMed ID: 22988869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
    Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
    Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-599 regulates the development of Parkinson's disease through mediating LRRK2 expression.
    Wu Q; Xi DZ; Wang YH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):724-731. PubMed ID: 30720180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease.
    Botta-Orfila T; Sànchez-Pla A; Fernández M; Carmona F; Ezquerra M; Tolosa E
    Brain Res; 2012 Jul; 1466():152-7. PubMed ID: 22634372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity.
    Gorostidi A; Ruiz-Martínez J; Lopez de Munain A; Alzualde A; Martí Massó JF
    Neurogenetics; 2009 Apr; 10(2):157-9. PubMed ID: 19020907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
    Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
    Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.